Literature DB >> 15266423

Nicotine replacement therapy for smoking cessation.

C Silagy, T Lancaster, L Stead, D Mant, G Fowler.   

Abstract

BACKGROUND: The aim of nicotine replacement therapy (NRT) is to replace nicotine from cigarettes. This reduces withdrawal symptoms associated with smoking cessation thus helping resist the urge to smoke cigarettes.
OBJECTIVES: The aims of this review were:to determine the effectiveness of the different forms of NRT (chewing gum, transdermal patches, nasal spray, inhalers and tablets) in achieving abstinence from cigarettes, or a sustained reduction in amount smoked; to determine whether the effect is influenced by the clinical setting in which the smoker is recruited and treated, the dosage and form of the NRT used, or the intensity of additional advice and support offered to the smoker; to determine whether combinations of NRT are more effective than one type alone; to determine its effectiveness compared to other pharmacotherapies. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group trials register in March 2004. SELECTION CRITERIA: Randomized trials in which NRT was compared to placebo or to no treatment, or where different doses of NRT were compared. We excluded trials which did not report cessation rates, and those with follow up of less than six months. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on the type of participants, the dose, duration and form of nicotine therapy, the outcome measures, method of randomization, and completeness of follow up. The main outcome measure was abstinence from smoking after at least six months of follow up. We used the most rigorous definition of abstinence for each trial, and biochemically validated rates if available. For each study we calculated summary odds ratios. Where appropriate, we performed meta-analysis using a Mantel-Haenszel fixed effect model. MAIN
RESULTS: We identified 123 trials; 103 contributing to the primary comparison between NRT and a placebo or non-NRT control group. The odds ratio (OR) for abstinence with NRT compared to control was 1.77 (95% confidence intervals (CI): 1.66 to 1.88). The ORs for the different forms of NRT were 1.66 (95% CI: 1.52 to 1.81) for gum, 1.81 (95% CI: 1.63 to 2.02) for patches, 2.35 (95% CI: 1.63 to 3.38) for nasal spray, 2.14 (95% CI: 1.44 to 3.18) for inhaled nicotine and 2.05 (95% CI: 1.62 to 2.59) for nicotine sublingual tablet/lozenge. These odds were largely independent of the duration of therapy, the intensity of additional support provided or the setting in which the NRT was offered. In highly dependent smokers there was a significant benefit of 4 mg gum compared with 2 mg gum (OR 2.20, 95% CI: 1.85 to 3.25). There was weak evidence that combinations of forms of NRT are more effective. Higher doses of nicotine patch may produce small increases in quit rates. Only one study directly compared NRT to another pharmacotherapy. In this study quit rates with bupropion were higher than with nicotine patch or placebo. REVIEWERS'
CONCLUSIONS: All of the commercially available forms of NRT (gum, transdermal patch, nasal spray, inhaler and sublingual tablets/lozenges) are effective as part of a strategy to promote smoking cessation. They increase the odds of quitting approximately 1.5 to 2 fold regardless of setting. The effectiveness of NRT appears to be largely independent of the intensity of additional support provided to the smoker. Provision of more intense levels of support, although beneficial in facilitating the likelihood of quitting, is not essential to the success of NRT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15266423     DOI: 10.1002/14651858.CD000146.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  226 in total

1.  Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration.

Authors:  Olivier George; Allison Lloyd; F Ivy Carroll; M Imad Damaj; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

2.  [Risk factor "smoking" : smoking cessation in patients with cardiovascular diseases].

Authors:  J Weil; J Stritzke; H Schunkert
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

3.  A randomized, controlled trial of NRT-aided gradual vs. abrupt cessation in smokers actively trying to quit.

Authors:  John R Hughes; Laura J Solomon; Amy E Livingston; Peter W Callas; Erica N Peters
Journal:  Drug Alcohol Depend       Date:  2010-05-26       Impact factor: 4.492

4.  Oral tobacco products: preference and effects among smokers.

Authors:  Dorothy K Hatsukami; Joni Jensen; Amanda Anderson; Berry Broadbent; Sharon Allen; Yan Zhang; Herb Severson
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

5.  Distinct beliefs, attitudes, and experiences of Latino smokers: relevance for cessation interventions.

Authors:  Michael C Zinser; Fred C Pampel; Estevan Flores
Journal:  Am J Health Promot       Date:  2011 May-Jun

Review 6.  Novel pharmacotherapeutic treatments for cocaine addiction.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  BMC Med       Date:  2011-11-03       Impact factor: 8.775

Review 7.  Pharmacotherapy for tobacco cessation: nicotine agonists, antagonists, and partial agonists.

Authors:  Maher Karam-Hage; Paul M Cinciripini
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

Review 8.  Pharmacogenetics and smoking cessation with nicotine replacement therapy.

Authors:  Riju Ray; Robert A Schnoll; Caryn Lerman
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  Smoking cessation: significance and implications for children.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 10.  Over-the-counter nicotine replacement therapy: can its impact on smoking cessation be enhanced?

Authors:  Nancy Amodei; R J Lamb
Journal:  Psychol Addict Behav       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.